CD235a/GYPA Protein (AA 20-91) (Fc Tag)

N° du produit ABIN7274765

Détail du produit

Antigène: CD235a/GYPA (GYPA) (Glycophorin A (GYPA))

Type de proteíne: Recombinant

Attributs du protein: AA 20-91

Origine: Humain

Source: HEK-293 Cells

Purification/Conjugué: Cette CD235a/GYPA protéine est marqué à la Fc Tag.

Fonction: Human GPA Protein

Séquence: Ser20-Glu91

Attributs du produit: Recombinant Human GPA Protein is expressed from HEK293 with hFc tag at the C-Terminus.It contains Ser20-Glu91.

Pureté: > 95 % as determined by Tris-Bis PAGE,> 95 % as determined by HPLC

Stérilité: 0.22 μm filtered

niveau d'endotoxine: Less than 1EU per μg by the LAL method.

Biological Activity Comment: The affinity constant of 1.16 μM as determined in SPR assay (Biacore T200). See testing image for detail.

Information d'application

Restrictions: For Research Use only

Stockage

Format: Lyophilized

Reconstitution: Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/mL is recommended. Dissolve the lyophilized protein in distilled water.

Buffer: Lyophilized from 0.22μm filtered solution in PBS ( pH 7.4). Normally 8 % trehalose is added as protectant before lyophilization.

Stock: -20 °C,-80 °C

Stockage commentaire: -20 to -80°C for 12 months as supplied from date of receipt., -80°C for 3-6 months after reconstitution., 2-8°C for 2-7 days after reconstitution., Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.

Date de péremption: 12 months

Détail du antigène

Antigène: CD235a/GYPA (GYPA) (Glycophorin A (GYPA))

Autre désignation: GPA (GYPA Produits)

Synonymes: GYPA Protein, gpa Protein, AI853584 Protein, CD235a Protein, GPA Protein, GPErik Protein, GPSAT Protein, HGpMiV Protein, HGpMiXI Protein, HGpSta(C) Protein, MN Protein, MNS Protein, PAS-2 Protein, glycophorin A (MNS blood group) Protein, glycophorin A Protein, GYPA Protein, Gypa Protein

Sujet: Granulomatosis with polyangiitis (GPA) presents a wide spectrum of manifestations from the common respiratory symptoms to infrequent neurological and cardiac complications. The challenge in diagnosis and management makes the rapidly progressive disorder one of the most challenging dilemmas in clinical medicine.The ultimate goal is an improved prognosis through outcome measures which assesses the disease control with minimal adverse effects of intensive immunosuppressive regimens, an integral part of the clinical approach to improve the quality of life of GPA patients.

Poids moléculaire: 34.7 kDa. Due to glycosylation, the protein migrates to 45-70 kDa based on Tris-Bis PAGE result.

Pathways: Maintenance of Protein Location